¶ Choroid Plexus Epithelial Cells - Expanded
Choroid Plexus Epithelial Cells Expanded is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Choroid Plexus Epithelial Cells (CPECs) are specialized ependymal cells that form the blood-cerebrospinal fluid barrier (BCSFB). These cells are responsible for producing cerebrospinal fluid (CSF) and regulating the exchange of molecules between the blood and the CNS.
- Location: Within choroid plexus villi in lateral, third, and fourth ventricles
- Morphology: Cuboidal epithelium with apical microvilli and basolateral infoldings
- Junctions: Tight junctions (claudin-1, claudin-2, occludin, ZO-1)
- Surface area: ~50% of total CSF-producing surface in humans
- Transthyretin (TTR) — Primary CSF protein synthesized by CPECs
- Aquaporin 1 (AQP1) — Water channel for CSF secretion
- Na+/K+ ATPase — Ion transport
- Carbonic anhydrase II — CSF pH regulation
- Claudin-2 — Paracellular water channels
- Produces ~500 mL of CSF daily in adults
- Active secretion via:
- Na+/K+ ATPase pumping Na+ into CSF
- Aquaporin-1 mediated water flow
- Carbonic anhydrase activity
- Cl- and HCO3- transport
- Tight junctions prevent paracellular diffusion
- Selective transporter-mediated transcellular passage
- Protects CNS from blood-borne substances
- CSF contains immune cells monitored by choroid plexus
- Gateway for peripheral immune cell entry
- Produces cytokines and chemokines
- Aβ clearance: Choroid plexus clears Aβ from CSF
- TTR-Aβ interaction: Transthyretin binds Aβ, potential therapeutic
- Barrier breakdown: Age-related BCSFB dysfunction
- Inflammation: Increased pro-inflammatory cytokines
- Alpha-synuclein transport through CSF
- Choroid plexus as potential entry point for pathogens
- Altered protein clearance
- Impaired CSF production
- Altered barrier permeability
- Reduced transthyretin levels
- Choroid plexus barrier dysfunction
- Altered immune cell trafficking
- CSF compositional changes
- Altered BCSFB permeability
- Enhanced immune cell entry
- Cytokine dysregulation
- NF-κB activation: Pro-inflammatory cytokine production
- JAK/STAT signaling: Immune response modulation
- Complement activation: Alternative pathway involvement
Choroid plexus-derived CSF biomarkers:
- Transthyretin: Decreased in AD, ALS
- Aβ isoforms: Diagnostic for AD
- Tau and p-tau: Neurodegeneration markers
- Cytokines: IL-6, TNF-α, IL-1β
- Transthyretin stabilization: Diflunisal, tafamidis
- BCSFB modulation: Tight junction modifiers
- CSF flow enhancement: Surgical approaches
- Gene therapy: AAV-mediated gene delivery
- Cell replacement: Stem cell-derived CPECs
- Nanoparticle delivery: Targeted CNS drug delivery via choroid plexus
- Decreased CSF production (~0.07% per year)
- Tight junction integrity decline
- Reduced transepithelial transport
- Increased inflammation
- Choroid plexus calcification
The study of Choroid Plexus Epithelial Cells Expanded has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Spector et al., Choroid plexus and CSF in neurodegenerative disease (2015)
- Johansson, The choroid plexus and CSF as a niche for neural stem cells (2013)
- Redzic et al., The choroid plexus and blood-CSF barrier in drug delivery (2014)
- Barake et al., Transthyretin and neuroprotection (2018)
- Kaur et al., Choroid plexus in aging and Alzheimer's disease (2016)
The choroid plexus produces CSF and is affected in Alzheimer's Disease, showing alterations in CSF dynamics and barrier function.